You are viewing the site in preview mode

Skip to content


  • Poster presentation
  • Open Access

Prognostic factors related to dendritic cell vaccines on patients with advanced non-small cell lung cancers: a multicenter analysis

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9 and
  • 10
Journal for ImmunoTherapy of Cancer20153 (Suppl 2) :P451

  • Published:


  • Pancreatic Cancer
  • Dendritic Cell
  • Prospective Randomized Trial
  • Cancer Vaccine
  • Advanced Pancreatic Cancer


Dendritic cell (DC)-based cancer vaccines may have a significant benefit to patients with advanced non-small cell lung cancers (NSCLCs). However, variations among clinical studies make it difficult to compare clinical outcomes. J-SICT DC vaccine study group is composed of the multi-medical centers in Japan, has provided DC vaccines as a compassionate use under the unified regimens for cell production and patient treatment, and published a number of clinical data of patients treated with DC vaccines. A single medical institution of this group has recently published a potentially beneficial effect of DC vaccines on overall survival of 62 patients with advanced NSCLCs[1]. Here we extended the findings to 260 patients with advanced NSCLCs who treated among 6 centers of this group.


Of 337 patients who met the inclusion criteria, 260 patients who received by weekly more than 5-times of peptide-pulsed DC vaccines were analyzed.


No serious adverse event related to DC vaccination. The mean survival time from diagnosis was 33.0 months (95%CI=27.9–39.2, 85.5% in 1-year and 66.4% in 2-years), and that from the first vaccination was 13.8 months (95%CI=11.4–16.8, 53.5% in 1-year and 36.1% in 2-years). Similar to our previous findings obtained in the analysis for advanced pancreatic cancer[2], 30 mm and more in diameter of erythema reaction at the injected site was identified as the strongest factor correlating to the overall survival from 1st vaccine (> 30 mm: MST=20.4 months, n=135 and < 30 mm: MST=8.8 months, n=122, p < 0.0001) in uni- and multivariate analyses. Importantly, the size of erythema reaction was significantly correlated with ECOG-PS, neutrophil/lymphocyte (N/L) ratio, hemoglobin, C-reactive protein, and fever (over 38 oC) at the time of leukapheresis, suggesting that the good physical condition as well as less inflammatory reaction might be important to induce stronger reaction against DC vaccines.


This is the first report of a multicenter clinical study suggesting the feasibility and possible clinical benefit of DC vaccines in patients with advanced NSCLCs. These findings suggest the potential responders against DC vaccines, and need to be addressed in well-controlled prospective randomized trials.

Authors’ Affiliations

Seren Clinic Fukuoka, Fukuoka, Japan
Cell Processing Center, Shinshu University Hospital, Matsumoto, Nagano, Japan
Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan
Seren Clinic Nagoya, Nagoya, Aichi, Japan
Seren Clinic Kobe, Kobe, Hyogo, Japan
Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan
Cancer Center, Tottori University Hospital, Yonago, Tottori, Japan
Department of Advanced Immunotherapeutics, Kitasato University School of Pharmacy, Tokyo, Japan
Seren Clinic Tokyo, Tokyo, Japan
R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan


  1. Takahashi H, et al: Eur J Cancer. 2013, 49: 852-9.PubMedView ArticleGoogle Scholar
  2. Kobayashi M, et al: Cancer Immunol Immunother. 2014, 63: 797-806.PubMedView ArticleGoogle Scholar


© Takahashi et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.